Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
2.100
-0.990 (-32.04%)
At close: Oct 29, 2025, 4:00 PM EDT
2.090
-0.010 (-0.48%)
After-hours: Oct 29, 2025, 7:59 PM EDT
Akebia Therapeutics Employees
Akebia Therapeutics had 181 employees as of December 31, 2024. The number of employees increased by 14 or 8.38% compared to the previous year.
Employees
181
Change (1Y)
14
Growth (1Y)
8.38%
Revenue / Employee
$1,125,597
Profits / Employee
-$201,569
Market Cap
556.80M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 181 | 14 | 8.38% |
| Dec 31, 2023 | 167 | -38 | -18.54% |
| Dec 31, 2022 | 205 | -221 | -51.88% |
| Dec 31, 2021 | 426 | 46 | 12.11% |
| Dec 31, 2020 | 380 | 20 | 5.56% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
AKBA News
- 7 hours ago - FDA Pushback Prompts Akebia To Drop Broad Label Pursuit For Kidney Disease Drug - Benzinga
- 1 day ago - Akebia Therapeutics Provides Update on Vafseo for Non-Dialysis Patients - GlobeNewsWire
- 9 days ago - Akebia Therapeutics Announces Five Presentations at ASN Kidney Week 2025 - GlobeNewsWire
- 4 weeks ago - Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - Akebia Therapeutics, Inc. (AKBA) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 Transcript - Seeking Alpha
- 2 months ago - Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Akebia Therapeutics: Post-Earnings Dip Looks Like A Discounted Entry Ahead Of A Vafseo Inflection - Seeking Alpha
- 2 months ago - Akebia Therapeutics to Present at Upcoming Investor Conferences - GlobeNewsWire